<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="965">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04659187</url>
  </required_header>
  <id_info>
    <org_study_id>#3871</org_study_id>
    <nct_id>NCT04659187</nct_id>
  </id_info>
  <brief_title>CORONA Germany- Clinical Outcome and Risk in Hospitalized COVID-19 Patients - An Epidemiological Study From Germany</brief_title>
  <acronym>CORONA Germany</acronym>
  <official_title>&quot;CORONA Germany&quot; - Clinical Outcome and Risk in Hospitalized COVID-19 Patients - An Epidemiological Study From Germany</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asklepios proresearch</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Asklepios Kliniken GmbH &amp; Co. KGaA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Asklepios proresearch</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, observational, prospective, epidemiological cohort study at 45&#xD;
      hospitals in Germany, all part of a German hospital network. All hospitalized patients tested&#xD;
      positive for SARS-CoV-2 will be included.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      CORONA Germany is a multicenter, observational, prospective, epidemiological cohort study at&#xD;
      45 hospitals in Germany, all part of a German hospital network. From January 1st till&#xD;
      November 17th, 2020, all hospitalized patients tested positive for SARS-CoV-2 (severe acute&#xD;
      respiratory syndrome coronavirus 2) will be included. Demographical data and outcomes will be&#xD;
      assessed in the entire study cohort. In a subgroup, consisting of 7 hospitals, further&#xD;
      detailed data (e.g. baseline characteristics, laboratory values, medication, clinical events)&#xD;
      will be assessed. Additionally, there will be subgroups of patients with cardiovascular&#xD;
      events and prior or preexisting oncological diseases. There are two primary endpoints: 1.&#xD;
      Combination of all-cause death and/or need for mechanical ventilation and/or allocation to&#xD;
      intensive care unit (ICU). 2. Occurrence of a clinical manifest cardiovascular events. The&#xD;
      aim of the study is the development of a prediction model for the primary endpoints, whereas&#xD;
      the secondary endpoint is a comparison of mortality rates between the 1st (01/01/20-09/15/20)&#xD;
      and 2nd (15/09/20) infection wave. All endpoints will be verified by an Endpoint Review&#xD;
      Committee. A Steering Committee, consisting of representatives of the 45 hospitals, the trial&#xD;
      statistician and members of the scientific department, takes responsibility of the study&#xD;
      design and results.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 26, 2020</start_date>
  <completion_date type="Anticipated">July 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Composite of death and/or need for mechanical ventilation and/or admission to ICU</measure>
    <time_frame>9 months</time_frame>
    <description>Composite of death and/or need for mechanical ventilation and/or admission to ICU in patients hospitalized to COVID 19</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of a clinical manifest cardiovascular event</measure>
    <time_frame>9 months</time_frame>
    <description>Occurrence of a clinical manifest cardiovascular Event, defined as (1) cardiopulmonary resuscitation in cardiac arrest, (2) cardiogenic shock, (3) acute coronary artery syndrome, including ST-segment elevation myocardial infarction (STEMI) and non-ST-segment elevation myocardial infarction (NSTEMI), (4) acute myocarditis, (5) denovo cardiac arrhythmia, (6) arterial or venous thrombosis, (7) pulmonary artery embolism, (8) worsening of prior or new onset heart failure, (9) ischemic stroke</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall mortality and mortality rate</measure>
    <time_frame>9 months</time_frame>
    <description>Comparison of mortality rates between the 1st (01/01/20-09/15/20) and 2nd (15/09/20) infection wave</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Risk stratification score to predict the primary endpoints</measure>
    <time_frame>9 months</time_frame>
    <description>Risk stratification score to predict the primary endpoint in hospitalized COVID 19 patients in the subgroup of seven hospitals</description>
  </secondary_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Anticipated">4000</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>All hospitalized COVID-19 patients</arm_group_label>
    <description>All consecutive hospitalized patients, tested positive for SARS-CoV-2 at 45 Asklepios hospitals in Germany</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subgroup: Detailed cohort of 7 hospitals</arm_group_label>
    <description>Cohort of 7 hospitals with detailed data set</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subgroup with cardiovascular events</arm_group_label>
    <description>Definition: Patients hospitalized to COVID-19, who developed a cardiovascular event, defined as (1) cardiopulmonary resuscitation in cardiac arrest, (2) cardiogenic shock, (3) acute coronary artery syndrome, including ST-segment elevation myocardial infarction (STEMI) and non-ST-segment elevation myocardial infarction (NSTEMI), (4) acute myocarditis, (5) denovo cardiac arrhythmia, (6) arterial or venous thrombosis, (7) pulmonary artery embolism, (8) worsening of prior or new onset heart failure, (9) ischemic stroke</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subgroup with oncological patients</arm_group_label>
    <description>Definition: Patients hospitalized to COVID-19 with prior or preexisting oncological disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subgroup with critical ill COVID-19 patients</arm_group_label>
    <description>Definition: Patients hospitalized to COVID-19 with intensive care treatment</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        all consecutive hospitalized patients tested positive for SARS CoV-2 using a reliable test&#xD;
        method (mostly polymerase chain reaction test)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  hospitalized patients tested positive for SARS CoV-2 using a reliable test method&#xD;
             (mostly polymerase chain reaction test)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with negative SARS CoV-2 testing&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christoph U Herborn, Prof. MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asklepios Kliniken GmbH &amp; Co. KGaA</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nele Gessler, MD</last_name>
    <phone>+49-401818 85 30 69</phone>
    <email>n.gessler@asklepios.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Melanie Gunawardene, MD</last_name>
    <phone>+40-401818855412</phone>
    <email>m.gunawardene@asklepios.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Asklepios Fachkliniken München-Gauting</name>
      <address>
        <city>Gauting</city>
        <state>Bavaria</state>
        <zip>82131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jürgen Behr, Prof. MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lorenz Nowak, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinik St. Georg</name>
      <address>
        <city>Hamburg</city>
        <zip>20099</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ulrich-Frank Pape, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bertholt Bein, Prof. MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stephan Willems, Prof. MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinik Wandsbek</name>
      <address>
        <city>Hamburg</city>
        <zip>22043</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Thomas Hölting, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Martin Bergmann, Prof. MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinik Barmbek</name>
      <address>
        <city>Hamburg</city>
        <zip>22291</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Axel Stang, Prof. MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sebastian Wirtz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asklepios Kliniken GmbH &amp; Co. KGaA</name>
      <address>
        <city>Hamburg</city>
        <zip>22307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nele Gessler, MD</last_name>
    </contact>
    <investigator>
      <last_name>Christoph U Herborn, Prof. MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christian Glöckner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinik Nord</name>
      <address>
        <city>Hamburg</city>
        <zip>22417</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Klaus Herrlinger, Prof. MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tino Schnitgerhans, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asklepios Westklinikum Hamburg</name>
      <address>
        <city>Hamburg</city>
        <zip>22559</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Rüdiger Schreiber, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinik Altona</name>
      <address>
        <city>Hamburg</city>
        <zip>22763</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dirk Arnold, Prof. MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hans-Peter Hauber, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 8, 2020</study_first_submitted>
  <study_first_submitted_qc>December 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 9, 2020</study_first_posted>
  <last_update_submitted>December 15, 2020</last_update_submitted>
  <last_update_submitted_qc>December 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>Corona</keyword>
  <keyword>Risk factor</keyword>
  <keyword>SARS-CoV-2</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Individual patient data will be collected anonymously. Sharing is not planned.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

